CO-188 denial code
This product is only covered when used according to FDA recommendations
How to fix it
Appeal with literature supporting the use where the payer's policy allows off-label coverage.
How to prevent it
Check payer drug policy for covered indications before administration.
In practice
A practice administers a biologic by a route or at a frequency outside the approved labelling. The plan covers the product for the indication but returns CO-188 because the use did not conform to FDA recommendations.
This code reaches beyond indication into how the product was used — dose, route, frequency, patient population, and the conditions the labelling attaches to administration.
Confirm what the labelling actually specifies and whether the plan's policy accommodates variation. Where a recognised compendium supports the modified use, citing it directly is usually the strongest available argument.
What sits behind it
The distinction from CO-114 matters for the appeal. CO-114 concerns approval for the indication; CO-188 concerns conformity to the recommendations attached to an approved use. A drug can be approved for the condition and still be administered in a way the labelling does not describe.
Dose and frequency variations are the commonest triggers, particularly where clinical practice has moved ahead of labelling. Extended interval dosing and weight-based adjustments both appear in practice well before labelling catches up, and coverage lags the practice.
Because these products carry substantial cost, confirming coverage for the specific regimen rather than the product before administration is the control that matters. A single denied biologic claim can exceed a month of ordinary denial volume in value.
Related codes
Terms used here — Medical Necessity · Prior Authorization · HCPCS
How we handle it — Prior Authorization · Denial Management · Medical Coding
Primary sources
The rules behind CO-188, at the bodies that publish them.
- Medicare Coverage Database (LCD/NCD) (opens in a new tab)
Centers for Medicare & Medicaid Services — Searchable national and local coverage determinations. The direct answer to whether a diagnosis supports medical necessity for a given procedure.
- Medicare Benefit Policy Manual (opens in a new tab)
Centers for Medicare & Medicaid Services — What Medicare covers and under what conditions, as distinct from how a claim is processed. The starting point for any coverage or medical necessity question.
- Advance Beneficiary Notice of Noncoverage (ABN) (opens in a new tab)
Centers for Medicare & Medicaid Services — The form and the rules for issuing it. Whether a non-covered service can be billed to the patient usually turns on whether a valid ABN was obtained beforehand.
Looking for a different code? Search all 190 CARC and RARC codes
Questions about CO-188
CO-114 concerns whether the product is approved for the indication at all. CO-188 concerns whether it was used in accordance with the recommendations attached to an approved use — dose, route, frequency and population. A product can clear the first test and fail the second.
Dose and frequency variations, particularly where clinical practice has advanced beyond the labelling. Extended interval dosing and weight-based adjustments both appear in routine practice before labelling and coverage policy catch up with them.
By verifying coverage for the specific regimen rather than the product before administration, and obtaining authorisation where available. A single denied biologic claim can outweigh a month of ordinary denial volume, which justifies the pre-service check.
Find out what your denials are costing you
A free billing audit reviews your denial rate, AR aging and clean claim rate against industry benchmarks. Takes about two minutes to request. No sales pitch.
No setup fees · You pay when we collect · Pricing from 3% of net collections